Efficacy and safety of allogenic canine adipose tissue-derived mesenchymalstem cell therapy for insulin-dependent diabetes mellitus in four dogs: A pilotstudy

摘要

Mesenchymal stem cells (MSCs) possess regenerative and immunomodulatory properties andcan control the immune dysregulation that leads to β-cell destruction. Stem-celltransplantation could thus manage insulin-dependent diabetes mellitus (IDDM) in dogs. Inthis pilot study, we aimed to assess canine adipose tissue-derived MSCs (cAT-MSCs)transplantation as a treatment for canine diabetes mellitus. This study included four dogswith over a year of insulin treatment for IDDM, following diagnosis at the VeterinaryMedicine Teaching Hospital of Seoul National University. Allogenic cAT-MSCs were infusedintravenously three or five times monthly to dogs with IDDM. Blood and urine samples wereobtained monthly. General clinical symptoms, including changes in body weight, vitality,appetite, and water intake were assessed. Three of the four owners observed improvement ofvitality after stem cell treatment. Two of the four dogs showed improvement in appetiteand body weight, polyuria, and polydipsia. C-peptide has increased by about 5–15% in threeof the cases, and fructosamine and HbA1c levels have improved in two of the cases.Hyperlipidemia was resolved in two of the dogs, and there was no concurrent bacterialcystitis in any of the dogs. C-peptide secretion and lipid metabolism are associated withdiabetic complications. Improvement in these parameters following the treatment suggeststhat cAT-MSC transplantation in dogs with IDDM might help to improve their insulinsecretory capacity and prevent diabetic complications.